Health Wildcatters, a Dallas-based healthcare startup accelerator and MedCity News partner, unveiled its 14th cohort of startups this week. The group brings together 10 innovative companies representing the U.S., Canada, and Israel, with one-third female-founded or female-led. The cohort reflects a sustained investment in digital health and emerging care technologies as the sector rebounds after years of funding pressure.
The 2026 cohort addresses core healthcare challenges: drug discovery, disease diagnostics, hospital operations, workforce management, and chronic pain treatment. Several startups focus on artificial intelligence applications. Atomistic Insights develops physics-guided AI for protein dynamics and drug discovery, while DISCHARGEpath automates hospital discharge coordination using agentic AI. EquiShift predicts patient demand and generates staffing recommendations to reduce costs and clinician burnout.
Diagnostic and treatment innovation also features prominently. Calaris Diagnostics is developing saliva-based tests for early detection of fatty liver disease. SanaOculis is building a non-invasive neurostimulation device to halt glaucoma progression. Venom Biologics is developing non-opioid pain treatments derived from scorpion venom, targeting sodium channels in pain-sensing neurons.
Dr. Hubert Zajicek, Health Wildcatters co-founder and CEO, will moderate a panel at INVEST Digital Health on October 29. The discussion will focus on how providers are reshaping clinical strategy through consumer-centric convenience, matching the experience standards patients expect in retail and digital services. The panel includes leaders from Novellia, Kin Health, and Reperio Health.
Stronger Digital Health Funding Environment
The cohort announcement aligns with a surge in digital health investment. U.S. digital health startups raised $14.2 billion in 2025, the highest total since 2022, according to venture capital firm Rock Health. That represents a 35% increase from $10.5 billion raised in 2024.
Artificial intelligence companies captured outsized investor attention. AI-focused startups collected 54% of total digital health funding in 2025, up sharply from 37% in 2024. These companies also commanded a funding premium: average AI deal size was 19% larger than non-AI competitors.
Mega deals surged as well. Raises exceeding $100 million accounted for 42% of 2025 investment, the highest proportion since 2021. Deal count fell to 482 from 509 in 2024, but average deal size climbed to $29.3 million from $20.7 million, indicating investors concentrated capital in fewer, larger bets.
Major venture firms shaped the largest rounds. When Andreessen Horowitz or General Catalyst participated in Series A deals, average size reached $24.1 million, compared with $18.9 million without their involvement. By Series D and beyond, their participation nearly doubled average round size to $265.7 million versus $172 million without them.
Market Risks Beneath the Rally
Growth came with caution flags. Thirty-five percent of 2025 deals were unlabeled, lacking a Series designation, suggesting some companies faced difficulty meeting benchmarks for formal funding rounds. This remained elevated compared to single-digit rates before 2021, even though the proportion improved from 44% in 2023.
Rock Health cautioned that rapid funding cycles carry risk. “Speeding fundraising timelines can be risky, giving limited time between rounds to make progress as companies burn through cash,” the report noted. The authors questioned whether investor confidence in AI’s ability to accelerate product-market fit would prove justified.
Competition looms from incumbents. Legacy electronic health record vendors and companies like OpenAI have demonstrated interest in the healthcare sector, potentially challenging venture-backed startups for market share and talent. Zajicek remained optimistic about the cohort’s potential despite broader market headwinds. “These 10 startups have the potential to address some of healthcare’s most complex challenges and shape the future of care,” he said.
Mergers and acquisitions activity soared to 195 deals from 121 in 2024, suggesting some consolidation. Five digital health companies also achieved IPO status in 2025, including musculoskeletal care firm Hinge Health and chronic condition manager Omada Health. However, policy uncertainty and Medicaid coverage cuts ahead may slow future public exits.
INVEST Digital Health takes place October 29 at Pegasus Park in Dallas. Rock Health’s 2025 funding analysis documents the investment landscape shift toward AI and larger deal sizes, reflecting both investor appetite and competitive pressure in the sector.
